PET scans reveal hidden clues in breast cancer survival
NCT ID NCT07316439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 197 women with advanced breast cancer to compare survival between those whose tumors lost estrogen receptors (ER) and those with triple-negative disease. Researchers used a special PET scan to track receptor changes. The goal is to understand how these changes affect prognosis and guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-fluoroestradiol (FES) PET/CT imaging
- What this could lead to
- If successful, this could help doctors better predict outcomes for breast cancer patients whose tumors change hormone receptor status.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all breast cancer types or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?